NextCure (NXTC) Expected to Announce Earnings on Monday

NextCure (NASDAQ:NXTC) is expected to announce its Q3 2026 results after the market closes on Monday, November 2nd. Analysts expect the company to post earnings of ($0.90) per share for the quarter. Individuals are encouraged to explore the company’s upcoming Q3 2026 earnings results page for the latest details on the call scheduled for Wednesday, November 4, 2026 at 4:00 PM ET.

NextCure (NASDAQ:NXTC) last announced its earnings results on Thursday, August 6th. The company reported ($2.80) EPS for the quarter, missing the consensus estimate of ($1.95) by ($0.85).

NextCure Stock Performance

NextCure stock opened at $6.31 on Friday. NextCure has a fifty-two week low of $1.55 and a fifty-two week high of $15.74. The stock has a market cap of $22.78 million, a PE ratio of -0.73 and a beta of 1.33. The firm’s 50-day simple moving average is $6.10 and its 200 day simple moving average is $7.89.

Insider Buying and Selling

In related news, major shareholder Adar1 Capital Management, Llc bought 5,626 shares of the company’s stock in a transaction on Friday, October 23rd. The shares were purchased at an average cost of $4.83 per share, for a total transaction of $27,173.58. Following the completion of the purchase, the insider directly owned 728,045 shares in the company, valued at $3,516,457.35. The trade was a 0.78% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is accessible through this link. Insiders have bought a total of 10,851 shares of company stock valued at $53,704 over the last 90 days. Insiders own 11.90% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of analysts recently commented on NXTC shares. Weiss Ratings lowered NextCure from a “sell (d-)” rating to a “sell (e+)” rating in a report on Monday, October 26th. Wall Street Zen upgraded NextCure from a “sell” rating to a “hold” rating in a research note on Saturday, August 15th. Finally, HC Wainwright reaffirmed a “buy” rating on shares of NextCure in a research report on Thursday, August 13th. Two equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average price target of $19.00.

NextCure Company Profile

NextCure, Inc (NASDAQ: NXTC) is a clinical-stage biotechnology company focused on developing immunomedicines for the treatment of cancer. The company’s research is aimed at identifying and targeting biological mechanisms that suppress the immune system’s ability to recognize and attack tumor cells.

NextCure’s product candidates have included NC318, an antibody designed to target Siglec-6, and NC410, a fusion protein intended to block the LAIR-1 immune-suppressive pathway. These programs have been evaluated in early-stage clinical studies involving patients with advanced solid tumors, with the goal of developing treatments that may restore or enhance anti-tumor immune responses.

Founded in 2015 and headquartered in the United States, NextCure has operated primarily as a research and development company serving the global oncology market through clinical trials and collaborations.